Oxymorphone HCl (Oxymorphone HCl) Patent Expiration, LOE Window & CMS Spending

Oxymorphone HCl (Oxymorphone HCl) by KVK-Tech: Multi-Source Generic Molecule, 6 AB generics, $409K 2024 CMS Part D & Medicaid spend, and 45 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorKVK-Tech
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$409K
2024 Medicare Part D Spend$379K
2024 Medicaid Spend$30K
Reported Wholesale Price Change (CA SB 17)45 WAC filings (max 1073.1% 2-yr change)